New ADIPOA2 research published from Centre Hospitalier Universitaire Montpellier

‘Mesenchymal stem cells derived exosomes and microparticles protect cartilage and bone from degradation in osteoarthritis’ by authors: Stella CosenzaMaxime RuizKarine ToupetChristian Jorgensen & Danièle Noël was published online on 24 November 2017 in the open access Nature publication Scientific Reports.

Abstract: Mesenchymal stem or stromal cells (MSCs) exert chondroprotective effects in preclinical models of osteoarthritis (OA). Most of their therapeutic effects are mediated via soluble mediators, which can be conveyed within extracellular vesicles (EVs). The objective of the study was to compare the respective role of exosomes (Exos) or microvesicles/microparticles (MPs) in OA. MPs and Exos were isolated from bone marrow murine BM-MSCs through differential centrifugation. Effect of MPs or Exos was evaluated on OA-like murine chondrocytes and chondroprotection was quantified by RT-qPCR. In OA-like chondrocytes, BM-MSC-derived MPs and Exos could reinduce the expression of chondrocyte markers (type II collagen, aggrecan) while inhibiting catabolic (MMP-13, ADAMTS5) and inflammatory (iNOS) markers. Exos and MPs were also shown to protect chondrocytes from apoptosis and to inhibit macrophage activation. In vivo, Exos or MPs were injected in the collagenase-induced OA (CIOA) model and histomorphometric analyses of joints were performed by µCT and confocal laser microscopy. BM-MSCs, MPs and Exos equally protected mice from joint damage. In conclusion, MPs and Exos exerted similar chondroprotective and anti-inflammatory function in vitro and protected mice from developing OA in vivo, suggesting that either Exos or MPs reproduced the main therapeutic effect of BM-MSCs.

Read more about the role of Centre Hospitalier Universitaire Montpellier in ADIPOA2 here.

Scientific Reports 7, Article number 16214 (2017)

Doi: 10.1038/s4 1598-017-15376-8

Published online 24 November 2017-11-29

Read the entire paper here.

 

 

ADIPOA2 meets the public at the Galway Science & Technology Festival 2017

ADIPOA-2 researchers at NUI Galway exhibited at the Galway Science and Technology Forum on 26 November 2017. In excess of 20,000 people attended the exhibition day. The NUI Galway regenerative medicine stand was the brainchild of Dr Siobhán Gaughan who works across several EU-funded stem cell projects coordinated at NUI Galway. Researchers Georgina Shaw, Amy Burke and Eka Mukeria, along with Siobhán Gaughan were on hand to explain the cell research ongoing at the university, the objectives and mission of ADIPOA-2, and to inspire the next generation of stem cell scientists. Several activities were on exhibition.

Microscopes were on hand to display bone marrow-derived MSCs and cells differentiated into fat cells. This display was used as an aid to discuss or explain how we need stem cells in our body to replace dead cells in our body and how these stem cells can differentiate down different pathways to make new fat, bone, skin and muscle.

Anatomical models were exhibited to explain the importance of the three EU-funded clinical trials involving stem cells that currently taking place through the Regenerative Medicine Institute (REMEDI) at NUI Galway:

  • ADIPOA-2 is treating osteoarthritis using adipose-derived stromal cells.  Cells are isolated from fat tissue procured by liposuction, expanded under GMP (good manufacturing practices) conditions in Centre for Cell Manufacturing in Ireland (CCMI), the cell manufacturing facility at NUI Galway and injected into the knee of people with osteoarthritis.  The treatment aims to reduce the pain and inflammation.
  • VISICORT project aims to treat corneal transplant rejection by using an infusion of human bone marrow-derived stromal cells obtained from healthy bone marrow donors.  The cells are expanded in CCMI cell manufacturing facility as a cell product, frozen and shipped to Charite Hospital in Berlin where corneal transplant patients will be treated.  The cell therapy used in this trial aims to reduce the risk of rejection of the corneal transplant.
  • NEPHSTROM is a project involving a clinical trial which aims to treat diabetic kidney disease using bone marrow-derived stem cells. Complications of diabetes were explained to help contextualise this project and a diabetic foot model with a black toe was also on hand.

AUTOSTEM is an EU-funded project to develop a robotic clean room platform system for the manufacture of large quantities of cells in bioreactors.  These large quantities of therapeutic cells will be required once cell therapy clinical trial results prove successful and a cohort of patients will be line up for treatment worldwide. The AUTOSTEM video ran on a loop for display to the public.

Special thanks to Dr Paul Lohan for tech support with the films and Dr Georgina Shaw for supplying the cells for display. Also to Ning Ge and Yicheng Ding of the iPS cell group at REMEDI led by Prof Sanbing Shen.

For more photos and information about the Galway Science & Technology Festival 2017, please follow us on Twitter @Adipoa2

For more information on the projects mentioned, please see:

  • ADIPOA-2 http://adipoa2.eu/ is led by Prof Frank Barry. Cartilage repair in the knee using stem cells derived from fat.
  • VISICORThttp://visicort.eu/ is coordinated by Prof Matthew Griffin. Infusions of bone marrow (BM)- derived stem cells to treat people with corneal transplants avoid transplant rejection.
  • NEPHSTROM http://nephstrom.eu/ Led by Prof Tim O’Brien. Infusions of BM-MSCs to treat patients with chronic kidney disease
  • AUTOSTEM http://www.autostem2020.eu/ is coordinated by Prof Mary Murphy. This project is developing a robotic platform and bioreactor which will grow the many cells required to treat future patients. A model bioreactor was available for demonstration.

Galway Advertiser Science Week 2017

ADIPOA2 is presented at the START competition in May 2017, Galway

Does it help your fitness to have an event as a goal when you are training? Can cartoons and comics help children to achieve better results in tests? How would you even find out?

Dr Siobhán Gaughan, NUI Galway Programmme Manager of ADIPOA-2, VISICORT and AUTOSTEM was on hand at the awards ceremony for a schools’ competition called “START” whose aim was to encourage school students to come up with interesting questions and to design and run trials to answer them in a scientific way.

“It is one of the only initiatives out there that is teaching children about randomised trials,” says Dr Sandra Galvin, who co-ordinates the Health Research Board Trials Methodology Research Network, which runs the START initiative. “We need more people to participate in trials to improve healthcare, so there is that big important picture here, and it comes down to kids having fun and they take the message home.” For more information about taking part, see hrb-tmrn.ie/start-competition.

Siobhán created and managed a presentation area for the three projects, spoke to the school groups and visitors who were interested in the planned clinical trials for ADIPOA-2 and VISICORT taking place at NUI Galway’s Clinical Research Facility. A sister project, AUTOSTEM was also represented. This project is looking ahead of the clinical trials in order to meet the needs of the clinics in the future by developing automated cell factories to produce the vast quantities of cells which will be required should the clinical trials prove successful.

ADIPOA-2 will present at EU-MSC2 meeting in Leiden in September

Hosted by Leiden University Medical Center, the EU MSC2 2017 meeting in Leiden, NL on September 12th and 13th will assemble twelve EU-funded, mesenchymal stromal cell-focussed consortia. Projects to be presented include: REDDSTARREACH, NephstromSCIENCEVISICORT and Adipoa-2AUTOSTEMBOOSTB4, SEPCELL, RESSTORE,  RETHRIM, Stellar, MERLIN, and RESPINE. This two day, interactive meeting will be held at the Stadsgehoorzaal Leiden. Three overarching aspects of the EU-MSC2 meeting include: mechanisms of action and potency assays; an interactive panel discussion on product development, and product development and market authorisation in a changing regulatory landscape.

The objectives of the meeting are to:

  • Enhance knowledge-sharing between EU research groups working in the mesenchymal stromal cell biology domain
  • Engage with European Commission Project Officers and other stakeholders from International Society of Cellular Therapy, stem cell ethicists and the European Medicines Agency (EMA)
  • Assemble trans-disciplinary research groups working across the global health spectrum but with a common focus of mesenchymal stromal cell biology
  • Bring up-and-coming researchers together for networking purposes, and to explore future consortium building and international funding application opportunities

Expected impacts and outcomes:

  • Provide opportunities to develop new mesenchymal stromal cell networks
  • Disseminate the findings and challenges between MSC-focussed consortia
  • Improve the communication potential of research, outcomes and the value of the research
  • Explore potential for new commercial technologies
  • Collectively enhance the quality and impact of planned clinical trials

These EU-funded projects are:

  • Improving the quality of life for European citizens
  • Progressing the clinical translation of MSC research and developments

For more information, please visit EU MSC2 2017.
Register via Eventbrite by August 14 2017.
Read the EU-MSC2 2015 meeting report here.

ADIPOA2 Trial commences in Germany

ADIPOA2 partners Evangelisches Waldkrankenhaus Spandau today announced the enrollment of the first patients in the German arm of the ADIPOA2 trial.

ADIPOA2 announces the start of Italian trial

The ADIPOA2 has successfully secured regulatory approval for the Italian part of its clinical trial. Click here and here to see some of the coverage of this exciting news in the Italian media.

 

ADIPOA2 Trial Commences in Italy

ADIPOA2’s Italian partners, Instituto Ortopedico Rizzoli de Bologna, announce the launch of the Italian arm of the ADIPOA2 trial.

Click here for a copy of IOR’s press release.

ADIPOA2 researchers highlight the project at ICRS World Congress

copy-of-300-x-250-icrs-2016-call-for-abstracts_250

ADIPOA2 researchers Prof. Frank Barry and Dr Mary Murphy (NUIG) attended the 13th World Congress of the International Cartilage Repair Society in Sorrento, Italy, on 24th – 27th September. The work of the ADIPOA2 project was highlighted during the conference sessions.

ADIPOA2 discussed at A FACTT meeting

screen-shot-2016-10-06-at-19-33-02 ADIPOA2 was one of a number of projects discussed at the A FACTT meeting in Galway this week. A FACTT is an Action to Focus and Accelerate Cell-based Tolerance-Inducing Therapies, funded through the COST (European Cooperation in Science and Technology) Programme. The meeting is being hosted by NUIG and runs from 5-7 October.

ADIPOA2 at the CRFG Open House

unnamed